Blueprint Medicines Corporation Stock Insider Trading
Based on the 100 latest insides trades, we have calculated the insider power to be negative at a ratio of -2.176.
In total, the insiders bought 280 584 and sold 280 792 BPMC shares in the last 100 trades.
| Date | Action | Amount | Person | Type |
| Jan 06, 2023 | Buy | 7 950 | Tsai John | Stock Option (Right to Buy) |
| Jan 06, 2023 | Buy | 3 900 | Tsai John | Common Stock |
| Dec 05, 2022 | Sell | 10 000 | Albers Jeffrey W. | Stock Option (Right to Buy) |
| Dec 05, 2022 | Sell | 10 000 | Albers Jeffrey W. | Stock Option (Right to Buy) |
| Dec 05, 2022 | Sell | 20 000 | Albers Jeffrey W. | Common Stock |
| Dec 05, 2022 | Buy | 10 000 | Albers Jeffrey W. | Common Stock |
| Dec 05, 2022 | Buy | 10 000 | Albers Jeffrey W. | Common Stock |
| Nov 03, 2022 | Buy | 1 100 | Haviland Kate | Common Stock |
| Nov 03, 2022 | Sell | 533 | Rossi Christina | Common Stock |
| Oct 04, 2022 | Sell | 3 477 | Namouni Fouad | Common Stock |
| Aug 24, 2022 | Sell | 5 000 | Durso-bumpus Debra | Stock Option (Right to Buy) |
| Aug 24, 2022 | Sell | 5 000 | Durso-bumpus Debra | Common Stock |
| Aug 24, 2022 | Buy | 5 000 | Durso-bumpus Debra | Common Stock |
| Aug 22, 2022 | Sell | 8 410 | Albers Jeffrey W. | Stock Option (Right to Buy) |
| Aug 22, 2022 | Sell | 662 | Albers Jeffrey W. | Common Stock |
| Aug 22, 2022 | Sell | 7 748 | Albers Jeffrey W. | Common Stock |
| Aug 22, 2022 | Buy | 8 410 | Albers Jeffrey W. | Common Stock |
| Aug 19, 2022 | Sell | 1 590 | Albers Jeffrey W. | Stock Option (Right to Buy) |
| Aug 19, 2022 | Sell | 1 590 | Albers Jeffrey W. | Common Stock |
| Aug 19, 2022 | Buy | 1 590 | Albers Jeffrey W. | Common Stock |
| Aug 16, 2022 | Sell | 10 000 | Albers Jeffrey W. | Stock Option (Right to Buy) |
| Aug 16, 2022 | Sell | 10 000 | Albers Jeffrey W. | Stock Option (Right to Buy) |
| Aug 16, 2022 | Sell | 293 | Albers Jeffrey W. | Common Stock |
| Aug 16, 2022 | Sell | 12 477 | Albers Jeffrey W. | Common Stock |
| Aug 16, 2022 | Sell | 7 230 | Albers Jeffrey W. | Common Stock |
| Aug 16, 2022 | Buy | 10 000 | Albers Jeffrey W. | Common Stock |
| Aug 16, 2022 | Buy | 10 000 | Albers Jeffrey W. | Common Stock |
| Aug 08, 2022 | Sell | 2 830 | Albers Jeffrey W. | Stock Option (Right to Buy) |
| Aug 08, 2022 | Sell | 7 170 | Albers Jeffrey W. | Stock Option (Right to Buy) |
| Aug 08, 2022 | Sell | 10 000 | Albers Jeffrey W. | Common Stock |
About Blueprint Medicines Corporation
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally avail... BPMC Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
